Source comparison
TB-500 Studied Hair Loss: Research Comparison
Mouse model (J Dermatol Sci 2019) 500mcg subcutaneous every other day for 8 weeks 27% increase in follicle density vs control Thymosin Beta-4 upregulated dermal papilla cell proliferation and reduced apoptosis during telogen-anagen transition Animal-only data.
This comparison does not assign a generated winner or score.
- Mouse model (J Dermatol Sci 2019)
- 500mcg subcutaneous every other day for 8 weeks
- 27% increase in follicle density vs control
- Thymosin Beta-4 upregulated dermal papilla cell proliferation and reduced apoptosis during telogen-anagen transition
- Animal-only data. Dosing and delivery don't translate directly to human scalp without clinical trials
- Rat wound healing model (Wound Repair Regen 2018)
- 750mcg subcutaneous twice weekly for 4 weeks
- Accelerated capillary formation and tissue granulation
- VEGF upregulation and actin-mediated endothelial migration
- Demonstrates angiogenic capacity but wasn't designed to measure follicular effects
- Human ex vivo follicle culture (PLOS ONE 2017)
- 10mcg/mL applied to culture medium for 72 hours
- Increased anagen phase duration by 18% in isolated follicles
- Enhanced actin dynamics during follicle stem cell migration
- Lab culture conditions don't replicate in vivo scalp environment or systemic peptide delivery
- No dedicated human clinical trials
- N/A
- TB-500 studied hair loss lacks Phase I, II, or III human trials as of 2026